{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:35:07Z","timestamp":1790393707092,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["TRA-056"],"award-info":[{"award-number":["TRA-056"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI20 \/ 00146"],"award-info":[{"award-number":["ICI20 \/ 00146"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116882","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T23:56:57Z","timestamp":1718323017000},"page":"116882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Use of CYP2D6 substrates and inhibitors during pain management with analgesic opioids: Drug-drug interactions that lead to lack of analgesic effectiveness"],"prefix":"10.1016","volume":"176","author":[{"given":"J.","family":"Muriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Escorial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Carratal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Margarit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Barrachina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MK","family":"Kringen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Peir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2024.116882_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.biopha.2024.116882_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2217\/pme-2017-0032","article-title":"Clinical application of pharmacogenetics in pain management","volume":"15","author":"Smith","year":"2018","journal-title":"Per Med"},{"issue":"4","key":"10.1016\/j.biopha.2024.116882_bib3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharm. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2024.116882_bib4","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41436-018-0431-8","article-title":"CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial","volume":"21","author":"Smith","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.biopha.2024.116882_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mayocpiqo.2020.08.009","article-title":"Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events","volume":"5","author":"Zhu","year":"2021","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"issue":"Suppl 11","key":"10.1016\/j.biopha.2024.116882_bib6","first-page":"S276","article-title":"Opioid pharmacokinetic drug-drug interactions","volume":"17","author":"Overholser","year":"2011","journal-title":"Am. J. Manag Care"},{"issue":"7","key":"10.1016\/j.biopha.2024.116882_bib7","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FPC.0000000000000057","article-title":"PharmGKB summary: tramadol pathway","volume":"24","author":"Gong","year":"2014","journal-title":"Pharm. Genom."},{"issue":"2","key":"10.1016\/j.biopha.2024.116882_bib8","first-page":"115","article-title":"Metabolism and Disposition of Prescription Opioids: A Review","volume":"27","author":"DePriest","year":"2015","journal-title":"Forensic Sci. Rev."},{"issue":"27","key":"10.1016\/j.biopha.2024.116882_bib9","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1056\/NEJMoa041888","article-title":"Codeine intoxication associated with ultrarapid CYP2D6 metabolism","volume":"351","author":"Gasche","year":"2004","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.biopha.2024.116882_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/17425255.2022.2085552","article-title":"CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia","volume":"18","author":"Ballester","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2024.116882_bib11","doi-asserted-by":"crossref","first-page":"j1224","DOI":"10.1136\/bmj.j1224","article-title":"The growing problem of co-treatment with opioids and benzodiazepines","volume":"356","author":"Karaca-Mandic","year":"2017","journal-title":"Bmj"},{"key":"10.1016\/j.biopha.2024.116882_bib12","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2147\/DDDT.S199574","article-title":"Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6","volume":"13","author":"Lee","year":"2019","journal-title":"Drug Des. Devel Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.116882_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40268-019-00282-3","article-title":"Prediction of Drug-Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation","volume":"19","author":"Ji","year":"2019","journal-title":"Drugs R. D."},{"issue":"18","key":"10.1016\/j.biopha.2024.116882_bib14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"issue":"9 Suppl","key":"10.1016\/j.biopha.2024.116882_bib15","first-page":"S256","article-title":"Differential diagnosis: nociceptive and neuropathic pain","volume":"12","author":"Nicholson","year":"2006","journal-title":"Am. J. Manag Care"},{"issue":"10","key":"10.1016\/j.biopha.2024.116882_bib16","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1185\/030079906X132488","article-title":"painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain","volume":"22","author":"Freynhagen","year":"2006","journal-title":"Curr. Med Res Opin."},{"issue":"6","key":"10.1016\/j.biopha.2024.116882_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"issue":"22","key":"10.1016\/j.biopha.2024.116882_bib18","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1097\/00007632-200011150-00017","article-title":"The Oswestry Disability Index","volume":"25","author":"Fairbank","year":"2000","journal-title":"Spine (Philos. Pa 1976)"},{"issue":"4","key":"10.1016\/j.biopha.2024.116882_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","volume":"8","author":"Pergolizzi","year":"2008","journal-title":"Pain. Pr."},{"key":"10.1016\/j.biopha.2024.116882_bib20","unstructured":"T. Flockhart DA, D, McDonald, C., Desta, Z., The Flockhart Cytochrome P450 Drug-Drug Interaction Table, 2021. https:\/\/drug-interactions.medicine.iu.edu. 2023)."},{"key":"10.1016\/j.biopha.2024.116882_bib21","doi-asserted-by":"crossref","first-page":"091","DOI":"10.26502\/aimr.0061","article-title":"Global Pain State Questionnaire: Reliability, Validity, and Gender Gap","volume":"4","author":"Barrachina","year":"2021","journal-title":"Arch. Intern. Med. Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.116882_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2024.116882_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2011.287","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype","volume":"91","author":"Crews","year":"2012","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116882_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2024.116882_bib25","first-page":"514","article-title":"Neuraxial anesthesia for pain control after cesarean section: a prospective randomized trial comparing three different neuraxial techniques in clinical practice","volume":"82","author":"Kaufner","year":"2016","journal-title":"Minerva Anestesiol."},{"issue":"Suppl 2","key":"10.1016\/j.biopha.2024.116882_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2362.33.s2.3.x","article-title":"Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication","volume":"33","author":"Cascorbi","year":"2003","journal-title":"Eur. J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.biopha.2024.116882_bib27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10549-013-2585-z","article-title":"Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen","volume":"139","author":"Binkhorst","year":"2013","journal-title":"Breast Cancer Res Treat."},{"issue":"5","key":"10.1016\/j.biopha.2024.116882_bib28","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.mcna.2017.04.012","article-title":"Integrative Pain Management","volume":"101","author":"Bonakdar","year":"2017","journal-title":"Med Clin. North Am."},{"issue":"2","key":"10.1016\/j.biopha.2024.116882_bib29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/fcp.12168","article-title":"Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain","volume":"30","author":"de Moraes","year":"2016","journal-title":"Fundam. Clin. Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2024.116882_bib30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41431-021-00920-y","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)","volume":"30","author":"Matic","year":"2022","journal-title":"Eur. J. Hum. Genet"},{"issue":"12","key":"10.1016\/j.biopha.2024.116882_bib31","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1097\/j.pain.0000000000002637","article-title":"Drug-drug-gene interaction risk among opioid users in the U.S. Department of Veterans Affairs","volume":"163","author":"Chanfreau-Coffinier","year":"2022","journal-title":"Pain"},{"issue":"11","key":"10.1016\/j.biopha.2024.116882_bib32","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/17425255.2022.2160317","article-title":"CYP2D6 pharmacogenetics and phenoconversion in personalized medicine","volume":"18","author":"Nahid","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116882_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11111174","article-title":"Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs","volume":"11","author":"Michaud","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.biopha.2024.116882_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.sjpain.2017.09.009","article-title":"Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics","volume":"17","author":"Solhaug","year":"2017","journal-title":"Scand. J. Pain."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:45:47Z","timestamp":1781649947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224007662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"alternative-id":["S0753332224007662"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116882","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of CYP2D6 substrates and inhibitors during pain management with analgesic opioids: Drug-drug interactions that lead to lack of analgesic effectiveness","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116882"}}